Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers …
Archives de l’auteur : Marianne Duparc
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors Company honors Dr. Michael Watson for his significant impact as member of Board of Directors Lyon, France – February 23, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment …
Biopharma Public Opinion, Pricing, Politics
Osivax is designing future-proof influenza and Covid vaccines
Developing broad-spectrum vaccines that target the heart of mutating viruses
Osivax obtient 10 millions d’euros de Bpifrance pour son vaccin antigrippal universel
Osivax gets €10M influenza vaccine grant
Osivax stays in the hunt for universal flu vaccine with €10M research grant
Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study
Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study Phase 2a results demonstrate excellent safety profile alongside strong, dose-dependent immune response First patient enrolled in complementary Phase 2a dose optimization study Lyon, France – December 21st, 2021 – Osivax, a biopharmaceutical company focused …
Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases
Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases Encouraging safety and cellular immune response data as well as a promising reactogenicity profile warrant further evaluation of OVX836 in Phase 2a study Lyon, France – December 2nd, 2021 – Osivax, a biopharmaceutical company focused …